目的探讨单份非血缘脐血移植(UCBT)治疗儿童高危急性淋巴细胞白血病(ALL)的疗效。 方法回顾性分析2008年9月至2014年12月安徽医科大学附属省立医院采用UCBT治疗高危ALL儿童66例的临床资料。患儿均采用强化清髓性预处理方案,分别为全身照射/环磷酰胺/阿糖胞苷(TBI/Cy/Ara-C)13例,白消安/环磷酰胺/氟达拉滨(BU/Cy/Flu)47例,BU/Cy/Ara-C 6例。环孢素联合短程霉酚酸酯预防移植物抗宿主病(GVHD)。 结果所有患儿输入复温后脐血总有核细胞数为4.70(2.07~13.74)×107/kg,CD34+细胞中位数为2.40(0.73~9.89)×105/kg。移植后42 d中性粒细胞累积植入率为97.0%(64例),移植后120 d血小板累积植入率为87.6%(57例);中性粒细胞和血小板中位植入时间分别为移植后16(12~37) d和39(15~148) d。Ⅱ~Ⅳ度急性GVHD、Ⅲ~Ⅳ度急性GVHD和慢性GVHD发生率分别为27.3%(17例)、17.2%(10例)和10.3%(6例),可评估的360 d移植相关病死率为21.2%(14例),3年累积复发率为14.8%(9例),3年无病生存率和总体生存率分别为65.1%(45例)和67.6%(46例)。 结论UCBT是治疗儿童高危ALL的一种安全有效的方法。
Objective To analyze the clinical outcomes of single unrelated umbilical cord blood transplanta- tion(UCBT) in treating children with high risk acute lymphoblastic leukemia(ALL). Methods Between September 2008 and December 2014, a total of 66 consecutive pediatric patients with ALL received single UCBT treatment in De- partment of Hematology, Anhui Provincial Hospital Affiliated to Anhui Medical University. Myeloablative conditioning regimen was applied. The conditioning regimen consisted of total body irradiation (TBI)/ Cyclophosphamide (Cy)/ Cytarabine (Ara -C)in 13 patients,Busulfan( BU)/Cy/Fludarabine(Flu) in 47 patients and BU/Cy/Ara- C in 6 patients. All patients received a combination of Cyclosporine and Mycophenolate mofetil for the prophylaxis of graft - ver- sus - host disease (GVHD). Results The median dose of infused total nucleated cells and CD34 + cells were 4.70 (2.07 - 13.74 ) ×107/kg and 2.40 (0.73 -9. 89 )× 105/kg. The cumulative incidence of neutrophil cells engraftment at day +42 and platelet recovery at day + 120 was 97.0% (64 cases) at a median of 16( 12 -37) days after trans- plantation and 87.6% ( 57 cases ) with a median time of recovery of 39 ( 15 - 148 ) days, respectively. Incidence of grades Ⅱ-Ⅳ acute GVHD, grades Ⅲ - Ⅳacute GVHD and chronic GVHD were 27.3% (17 cases), 17.2% ( 10 cases) ,and 10.3% (6 cases) ,respectively. The transplant - related mortality at 360 day was 21.2% ( 14 cases). The 3 - year cumulative incidence of relapse was 14.8% (9 cases). The 3 - year - disease - free survival and overall survival rates were 65.1% (45 cases) and 67.6% (46 cases), respectively. Conclusions For pediatric patients with high risk ALL,UCBT is a safe and effective treatment option.